MedTrace Logo

Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic Shock

NCT06646224 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-10-17

No results posted yet for this study

Summary

This study aims to evaluate the safety and effectiveness of the CorVad Percutaneous Ventricular Assist System for providing circulatory support in patients with cardiogenic shock caused by cardiomyopathy. This will be assessed through a prospective, multicenter, single-arm clinical trial involving patients with cardiogenic shock. The focus will be on determining the device's ability to improve survival outcomes and reduce the risk of related adverse events in these patients.

Conditions

  • Cardiogenic Shock

Interventions

DEVICE

CorVad Percutaneous Ventricular Assist System

The CorVad Percutaneous Ventricular Assist System provides circulatory support for patients with cardiogenic shock.

Sponsors & Collaborators

  • Shenzhen Core Medical Technology CO.,LTD.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-12
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06646224 on ClinicalTrials.gov